Page last updated: 2024-11-08

4-allyl-2,6-dimethoxyphenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-allyl-2,6-dimethoxyphenol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-allyl-2,6-dimethoxyphenol : A member of the class of phenols that is phenol substituted by an allyl group at position 4 and methoxy groups at positions 2 and 6 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID226486
CHEMBL ID2059292
CHEBI ID86562
SCHEMBL ID293977
MeSH IDM0290837

Synonyms (60)

Synonym
2,6-dimethoxy-4-prop-2-enylphenol
phenol, 2,6-dimethoxy-4-(2-propenyl)-
phenol, 4-allyl-2,6-dimethoxy-
nsc60246
nsc-60246
4-hydroxy-3,5-dimethoxyallylbenzene
phenol,6-dimethoxy-
phenol,6-dimethoxy-4-(2-propenyl)-
6627-88-9
methoxyeugenol
2,6-dimethoxy-4-allylphenol
4-allyl-2,6-dimethoxyphenol
nsc16953
nsc-16953
inchi=1/c11h14o3/c1-4-5-8-6-9(13-2)11(12)10(7-8)14-3/h4,6-7,12h,1,5h2,2-3h
4-allyl-2,6-dimethoxyphenol, >=95%, fg
4-allyl-2,6-dimethoxyphenol, >=95%
BMSE010054
A835401
2,6-dimethoxy-4-prop-2-enyl-phenol
nsc 16953
einecs 229-600-2
unii-8vf00ywp89
ai3-23057
8vf00ywp89 ,
fema no. 3655
nsc 60246
2,6-dimethoxychavicol
CHEMBL2059292
chebi:86562 ,
BP-10517
FT-0636204
4-allyl-2,6-dimethoxyphenol [fhfi]
4-(2-propenyl)syringol
4-allylsyringol
2,6-dimethoxy-4-(2-propenyl)phenol
6-methoxyeugenol
phenol, 2,6-dimethoxy-4-(2-propen-1-yl)-
chavicol, 2,6-dimethoxy-
AKOS015888171
2,6-dimethoxy-4-(prop-2-en-1-yl)phenol
phenol,2,6-dimethoxy-4-(2-propen-1-yl)-
SCHEMBL293977
FWMPKHMKIJDEMJ-UHFFFAOYSA-N
phenol, 4-(2-propenyl)-2,6-dimethoxy
4-allyl-2,6-dimetoxyphenol
4-(2-propenyl)-2,6-dimethoxyphenol (4-allylsyringol)
DTXSID30216470
mfcd00008655
4-(2-propenyl)-2,6-dimethoxyphenol
2,6-dimethoxy-4-(2-propenyl)-phenol
phenol, 4-allyl-2,6-dimethoxy- (8ci)
4-allyl-2,6-dimethoxyphenol, 8ci
phenol, 2,6-dimethoxy-4-(2-propenyl)- (9ci)
4-allyl-2,6-dimethoxy-phenol
2,6-dimethoxy-4-(2-propenyl)phenol, 9ci
Q27159248
AS-36789
bdbm50242963
CS-0158007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
phenylpropanoidAny organic aromatic compound with a structure based on a phenylpropane skeleton. The class includes naturally occurring phenylpropanoid esters, flavonoids, anthocyanins, coumarins and many small phenolic molecules as well as their semi-synthetic and synthetic analogues. Phenylpropanoids are also precursors of lignin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sialidase AStreptococcus pneumoniaeIC50 (µMol)6.90000.30005.050010.0000AID1467530
Sialidase AStreptococcus pneumoniaeKi4.20000.10002.92839.4000AID1467531
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID671761Inhibition of SARS coronavirus nsP13 helicase activity expressed in Escherichia coli Rosetta assessed inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID671764Inhibition of HCV NS3 helicase ATP hydrolysis activity overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of inorganic phosphate release by AM/MG-based colometric analysis in the presence of M13 ssDNA2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1467531Noncompetitive inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by Lineweaver-Burk plot/Dixon plot analysis2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1467534Noncompetitive inhibition of Streptococcus pneumoniae sialidase NanC using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by Lineweaver-Burk plot/Dixon plot analysis2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1467530Inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1467529Inhibition of Streptococcus pneumoniae sialidase NanB using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID671762Inhibition of HCV NS3 helicase overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1256912Inhibition of human IDH1 R132H mutant expressed in IPTG-induced Escherichia coli BL21 cells assessed as oxidation of NADPH to NADP+ after 5 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID1467533Inhibition of Streptococcus pneumoniae sialidase NanC using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID1754175Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Tulipiferamide A, an Alkamide from
AID1256913Inhibition of human IDH1 expressed in IPTG-induced Escherichia coli BL21 cells assessed as reduction of NADP+ to NADPH after 5 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's1 (7.69)29.6817
2010's4 (30.77)24.3611
2020's7 (53.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.31 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]